new year, brilliant start! on january 11, at the 2022 global investment trend forum and the 6th golden hong kong stocks awards ceremony, alphamab oncology received the "most valuable pharmaceutical and medical company" award.
“golden hong kong stocks awards” is one of the largest and most authoritative awards for hong kong listed companies, aiming to recognize industry benchmarks with excellent overall quality such as performance, corporate governance, brand influence and capital market activity. alphamab oncology has received the award for two consecutive years since it was listed in hong kong in december 2019, demonstrating the long-term value of the company's continued pioneering innovation in the field of biopharmaceuticals.
in 2021, the world's first subcutaneously injected pd-l1 envafolimab, developed by alphamab oncology, has received marketing authorization from nmpa, the first phase iii pivotal clinical study of pd-l1/ctla-4 bispecific antibody kn046 in china (enreach-lung-01) has successfully completed enrollment of all patients, and the company entered an agreement with cspc for the development and commercialization of her2 bispecific antibody kn026 in mainland china. we continue to revolutionize the treatment regimens and extend the hope of survival for cancer patients.
in the future, alphamab oncology will adhere to the mission of " to make cancer manageable and curable", continue to adhere to the dual drive of innovation and internationalization, bring benefits to human health with better innovative drugs, and create value for shareholders and society.
about alphamab oncology
alphamab oncology is focusing on innovation, production and commercialization of anti-tumor drugs. on december 12, 2019, the company was listed in the mainboard of hong kong stock exchange with stock code 9966.
alphamab has fully integrated proprietary biologics platforms in bi-specifics and protein engineering. its highly differentiated in-house pipeline includes fifteen tumor monoclonal antibodies and bispecific antibodies and a covid-19 bispecific antibody. four products have advanced into phase i-iii clinical trials or pre-marketing stage in china, the united states, japan and australia. in november 2021, envafolimab received marketing authorization from the chinese national medical products administration (nmpa) for the treatment of previously treated msi-h/dmmr advanced solid tumors.
the company also has state-of-the-art manufacturing capabilities designed and built to meet nmpa and eu/fda’s cgmp standards and a complete quality system which has passed the on-site inspection of a european union qualified person. alphamab oncology is committed to building a global leading, multi-dimensional drug development and commercialization platform, focusing on multifunctional biological innovative drugs, and to benefit patients in china and around the world.
alphamab oncology forward-looking statements
this press release contains statements related to our future business and financial performance and future events or developments involving alphamab oncology that may constitute forward-looking statements. these statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. these statements may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. we may also make forward-looking statements in other reports, in presentations, in material delivered to shareholders and in press releases. in addition, our representatives may from time to time make oral forward-looking statements. such statements are based on the current expectations and certain assumptions of alphamab oncology’s management and business operation, many of which are difficult to predict and generally beyond alphamab oncology’s control. these are subject to a number of risks and uncertainties, including but not limited to, uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, alphamab oncology's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding and alphamab oncology’s disclosures. should one or more of these risks or uncertainties materialize,or should underlying expectations not occur or assumptions prove incorrect, actual results, performance or achievements of alphamab oncology may (negatively or positively) vary materially from those described explicitly or implicitly in the relevant forward-looking statement. other than as required by applicable law, alphamab oncology undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
